Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P, Jiang Y, Xu MJ, Lei KJ, Qu S, Wang XH, Jin YS, Zhao B, Dai R, Wang FH, Xu RH. Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial. Med. 2026 Apr 10; 7(4):101029.
-
Shin JH, Kim JY, Kim SH, Kang Y, Lee HJ, Kim MJ, Choi J, Jeong SK, Park SO, Cho YB, Kim KK, Shim JH, Chun E, Lee KY. USP11 promotes colorectal cancer progression by stabilizing EGFR and TRAF6: a potential therapeutic target in EGFR- and TLR-driven tumorigenesis. Cell Death Dis. 2025 Dec 19; 16(1):894.
-
Shin JH, Kim JY, Kim MJ, Kang Y, Lee HJ, Choi B, Lee JS, Kwon D, Kim SH, Sung Y, Kim DH, Shim JH, Chun E, Lee KY. PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways. Exp Mol Med. 2025 Nov; 57(11):2559-2573.
-
Fuster-Matanzo A, Pic?-Peris A, Bellv?s-Bataller F, Jimenez-Pastor A, Weiss GJ, Mart?-Bonmat? L, L?zaro S?nchez A, Bazaga D, Banna GL, Addeo A, Camps C, Seijo LM, Alberich-Bayarri ?. Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods. Eur Radiol. 2026 Mar; 36(3):2157-2185.
-
Raquel-Cunha A, Pinheiro J, Marques RF, Font?o P, Cardoso-Carneiro D, Mendes A, Gomes INF, Laus AC, da Silva-Oliveira RJ, Reis RM, Martinho O. RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR-targeted therapies. Mol Oncol. 2025 Nov; 19(11):3205-3222.
-
Yerramilli VS, Lin G, Reisinger JL, Hemmerlin RM, Lindberg SK, Plante K, Ross AH, Gericke A, Scarlata S. The scaffolding protein IQGAP1 enhances EGFR signaling by promoting oligomerization and preventing degradation. J Biol Chem. 2024 11; 300(11):107844.
-
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.
-
Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J, J?nne PA, Mino-Kenudson M, Swanson S, Wright CD, Kozono D, Marcoux P, Piotrowska Z, Sequist LV, Willers H. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist. 2024 07 05; 29(7):609-618.
-
Bugide S, Edwards YJK, Gupta R, Green MR, Wajapeyee N. CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proc Natl Acad Sci U S A. 2023 01 24; 120(4):e2218118120.
-
Kato T, Asakura T, Edwards CE, Dang H, Mikami Y, Okuda K, Chen G, Sun L, Gilmore RC, Hawkins P, De la Cruz G, Cooley MR, Bailey AB, Hewitt SM, Chertow DS, Borczuk AC, Salvatore S, Martinez FJ, Thorne LB, Askin FB, Ehre C, Randell SH, O'Neal WK, Baric RS, Boucher RC. Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. Am J Respir Crit Care Med. 2022 12 01; 206(11):1336-1352.